Tumor Bank

Last updated

A tumor bank is sometimes also referred to as a Tissue Bank, since normal tissues for research are also often collected. However, this function is distinct from a Tissue Bank which collects and harvests human cadaver tissue for medical research and education, and banks which store Biomedical tissue for organ transplantation.

Contents

Cancer Samples

Most tumor banks collect their tumor samples from discarded tissues not needed for pathologic diagnosis, after patients undergo surgery to remove the tumor. The method of sample preservation is critical, and must be compatible with the downstream analysis techniques. Tissue is often snap frozen in liquid nitrogen but may also be preserved in special fixative such as RNAlater (which preserves RNA and proteins), or formalin which preserves tissue architecture. [1] Proteins and RNA can readily be extracted and characterized from tissue preserved with either method. [2] [3]

Many Cancer Centers in the U.S. have a Tumor Bank to supply biomedical scientists with actual patient samples of cancer and associated adjacent normal tissue. This process is currently a high priority to support more Translational Research.

All institutional banks preserve tissue that may be used in research not necessarily related to the patient. Depending on the nationality and regulatory environment of the clinic, re-purposing of excised tissues and samples collected during the course of standard care for use in research may or may not require the consent of the patient. In some countries the patient loses control over their tissue immediately after the surgery or after some specified period of time, after which the material is classed as medical waste. In the US, samples may be collected and used with the patient's consent, or after some period of time defined by the clinic's Institutional Review Board samples may be considered exempt from consent under US 45CFR46, which governs the use of human subjects in research. [4] Many academic and institutional biobanks will not release samples to commercial or big pharma research labs, and some will not even release samples to other academic institutions, so there is a chronic shortage of oncology samples available for research. Additionally, sample availability is governed primarily by clinical standard care, and the trend towards starting chemical treatments immediately upon diagnosis is making it especially difficult to obtain pre-treatment surgically excised tumor samples and pre-treatment blood draws for some cancer indications.

In addition to the general practices of tumor banks, the Ontario Tumor Bank (OTB), operated by the Ontario Institute for Cancer Research, exemplifies a significant scale and scope in biobanking. The OTB has amassed a collection exceeding 100,000 specimens from over 20,000 patients, making it one of the largest of its kind in Canada. This extensive repository supports a wide range of cancer research studies, from molecular and genetic analysis to clinical trials. The ability to access such a large and diverse collection of samples has been instrumental in advancing our understanding of cancer and improving therapeutic strategies. This large-scale collection underscores the critical role that well-maintained and ethically governed tumor banks play in the advancement of translational cancer research.

Personalized medicine may influence clinical policies related to biobanking as treatments may increasingly use the genetic characteristics of each individual's own cancer to select or develop uniquely targeted therapies. If personal biobanking options are not available to patients in some locations, they may conceivably start looking for private tumor banks to preserve their own excised tumors for use in their own future therapies. The implications of this trend for ethical and regulatory issues related to existing institutional biobanking policies are not yet clear.

Anti-cancer vaccines of the first type (from the patient's own tumour cells) are much easier to make, which is why many patients start treatment with them. In order for specialists to be able to create such a vaccine, whether when a tumour is first diagnosed or 3-5-10 years later when relapse occurs, it is advisable to freeze some of the tumour cells. At any time, the cell culture is thawed and specially processed, after which it is used to create a personalised product. In metastatic cancer patients are often recommended a combination therapy with oncolytic viruses and drugs based [5] on the patient's own tissue, which also requires material from the cell bank. With this treatment it is possible to simultaneously activate the immune response (by acting on T-suppressors, checkpoint inhibitors) and enhance the anti-tumour effect of the immune system, by changing the function of the T-killer.

This provides an opportunity to develop digital design to create diagnostics, [6] create miniature organ-on-a-chip devices and, most importantly, create human 'digital twins' technology for personalised cancer therapy.

See also

Related Research Articles

<span class="mw-page-title-main">Histology</span> Study of the microscopic anatomy of cells and tissues of plants and animals

Histology, also known as microscopic anatomy or microanatomy, is the branch of biology that studies the microscopic anatomy of biological tissues. Histology is the microscopic counterpart to gross anatomy, which looks at larger structures visible without a microscope. Although one may divide microscopic anatomy into organology, the study of organs, histology, the study of tissues, and cytology, the study of cells, modern usage places all of these topics under the field of histology. In medicine, histopathology is the branch of histology that includes the microscopic identification and study of diseased tissue. In the field of paleontology, the term paleohistology refers to the histology of fossil organisms.

<span class="mw-page-title-main">Brain tumor</span> Neoplasm in the brain

A brain tumor occurs when abnormal cells form within the brain. There are two main types of tumors: malignant (cancerous) tumors and benign (non-cancerous) tumors. These can be further classified as primary tumors, which start within the brain, and secondary tumors, which most commonly have spread from tumors located outside the brain, known as brain metastasis tumors. All types of brain tumors may produce symptoms that vary depending on the size of the tumor and the part of the brain that is involved. Where symptoms exist, they may include headaches, seizures, problems with vision, vomiting and mental changes. Other symptoms may include difficulty walking, speaking, with sensations, or unconsciousness.

<span class="mw-page-title-main">Glioma</span> Tumour of the glial cells of the brain or spine

A glioma is a type of tumor that starts in the glial cells of the brain or the spine. Gliomas comprise about 30 percent of all brain tumors and central nervous system tumours, and 80 percent of all malignant brain tumours.

<span class="mw-page-title-main">Immunohistochemistry</span> Common application of immunostaining

Immunohistochemistry (IHC) is a form of immunostaining. It involves the process of selectively identifying antigens (proteins) in cells and tissue, by exploiting the principle of antibodies binding specifically to antigens in biological tissues. Albert Hewett Coons, Ernest Berliner, Norman Jones and Hugh J Creech was the first to develop immunofluorescence in 1941. This led to the later development of immunohistochemistry.

<span class="mw-page-title-main">Cancer immunotherapy</span> Artificial stimulation of the immune system to treat cancer

Cancer immunotherapy (immuno-oncotherapy) is the stimulation of the immune system to treat cancer, improving the immune system's natural ability to fight the disease. It is an application of the fundamental research of cancer immunology (immuno-oncology) and a growing subspecialty of oncology.

<span class="mw-page-title-main">Malignant peripheral nerve sheath tumor</span> Medical condition

A malignant peripheral nerve sheath tumor (MPNST) is a form of cancer of the connective tissue surrounding nerves. Given its origin and behavior it is classified as a sarcoma. About half the cases are diagnosed in people with neurofibromatosis; the lifetime risk for an MPNST in patients with neurofibromatosis type 1 is 8–13%. MPNST with rhabdomyoblastomatous component are called malignant triton tumors.

MammaPrint is a prognostic and predictive diagnostic test for early stage breast cancer patients that assess the risk that a tumor will metastasize to other parts of the body. It gives a binary result, high-risk or low-risk classification, and helps physicians determine whether or not a patient will benefit from chemotherapy. Women with a low risk result can safely forego chemotherapy without decreasing likelihood of disease free survival. MammaPrint is part of the personalized medicine portfolio marketed by Agendia.

<span class="mw-page-title-main">Nasopharyngeal carcinoma</span> Type of throat cancer; most common to occur in the nasopharynx

Nasopharyngeal carcinoma (NPC), or nasopharynx cancer, is the most common cancer originating in the nasopharynx, most commonly in the postero-lateral nasopharynx or pharyngeal recess, accounting for 50% of cases. NPC occurs in children and adults. NPC differs significantly from other cancers of the head and neck in its occurrence, causes, clinical behavior, and treatment. It is vastly more common in certain regions of East Asia and Africa than elsewhere, with viral, dietary and genetic factors implicated in its causation. It is most common in males. It is a squamous cell carcinoma of an undifferentiated type. Squamous epithelial cells are a flat type of cell found in the skin and the membranes that line some body cavities. Undifferentiated cells are cells that do not have their mature features or functions.

<span class="mw-page-title-main">Biobank</span> Repository of biological samples used for research

A biobank is a type of biorepository that stores biological samples for use in research. Biobanks have become an important resource in medical research, supporting many types of contemporary research like genomics and personalized medicine.

<span class="mw-page-title-main">Epithelioid sarcoma</span> Medical condition

Epithelioid sarcoma is a rare soft tissue sarcoma arising from mesenchymal tissue and characterized by epithelioid-like features. It accounts for less than 1% of all soft tissue sarcomas. It was first definitively characterized by F.M. Enzinger in 1970. It commonly presents itself in the distal limbs of young adults as a small, soft mass or a cluster of bumps. A proximal version has also been described, frequently occurring in the upper extremities. Less commonly, cases are reported in the pelvis, vulva, penis, and spine.

A biorepository is a facility that collects, catalogs, and stores samples of biological material for laboratory research. Biorepositories collect and manage specimens from animals, plants, and other living organisms. Biorepositories store many different types of specimens, including samples of blood, urine, tissue, cells, DNA, RNA, and proteins. If the samples are from people, they may be stored with medical information along with written consent to use the samples in laboratory studies.

<span class="mw-page-title-main">Oncology</span> Branch of medicine dealing with, or specializing in, cancer

Oncology is a branch of medicine that deals with the study, treatment, diagnosis, and prevention of cancer. A medical professional who practices oncology is an oncologist. The name's etymological origin is the Greek word ὄγκος (ónkos), meaning "tumor", "volume" or "mass". Oncology is concerned with:

<span class="mw-page-title-main">Biological specimen</span> Laboratory specimen used in biological research

A biological specimen is a biological laboratory specimen held by a biorepository for research. Such a specimen would be taken by sampling so as to be representative of any other specimen taken from the source of the specimen. When biological specimens are stored, ideally they remain equivalent to freshly-collected specimens for the purposes of research.

<span class="mw-page-title-main">Talimogene laherparepvec</span> Gene therapy medication

Talimogene laherparepvec, sold under the brand name Imlygic, is a biopharmaceutical medication used to treat melanoma that cannot be operated on; it is injected directly into a subset of lesions which generates a systemic immune response against the recipient's cancer. The final four year analysis from the pivotal phase 3 study upon which TVEC was approved by the FDA showed a 31.5% response rate with a 16.9% complete response (CR) rate. There was also a substantial and statistically significant survival benefit in patients with earlier metastatic disease and in patients who hadn't received prior systemic treatment for melanoma. The earlier stage group had a reduction in the risk of death of approximately 50% with one in four patients appearing to have met, or be close to be reaching, the medical definition of cure. Real world use of talimogene laherparepvec have shown response rates of up to 88.5% with CR rates of up to 61.5%.

<span class="mw-page-title-main">Oncolytic herpes virus</span>

Many variants of herpes simplex virus have been considered for viral therapy of cancer; the early development of these was thoroughly reviewed in the journal Cancer Gene Therapy in 2002. This page describes the most notable variants—those tested in clinical trials: G207, HSV1716, NV1020 and Talimogene laherparepvec. These attenuated versions are constructed by deleting viral genes required for infecting or replicating inside normal cells but not cancer cells, such as ICP34.5, ICP6/UL39, and ICP47.

Adenovirus varieties have been explored extensively as a viral vector for gene therapy and also as an oncolytic virus.

Patient derived xenografts (PDX) are models of cancer where the tissue or cells from a patient's tumor are implanted into an immunodeficient or humanized mouse. It is a form of xenotransplantation. PDX models are used to create an environment that allows for the continued growth of cancer after its removal from a patient. In this way, tumor growth can be monitored in the laboratory, including in response to potential therapeutic options. Cohorts of PDX models can be used to determine the therapeutic efficiency of a therapy against particular types of cancer, or a PDX model from a specific patient can be tested against a range of therapies in a 'personalized oncology' approach.

Interventional oncology is a subspecialty field of interventional radiology that deals with the diagnosis and treatment of cancer and cancer-related problems using targeted minimally invasive procedures performed under image guidance. Interventional oncology has developed to a separate pillar of modern oncology and it employs X-ray, ultrasound, computed tomography (CT) or magnetic resonance imaging (MRI) to help guide miniaturized instruments to allow targeted and precise treatment of solid tumours located in various organs of the human body, including but not limited to the liver, kidneys, lungs, and bones. Interventional oncology treatments are routinely carried out by interventional radiologists in appropriate settings and facilities.

Viralytics Ltd is an Australian biotechnology company working in the field of oncolytic viruses, that is, viruses that preferentially infect and kill cancer cells. The company's oncolytic virus product, called Cavatak, is currently in clinical trials in metastatic melanoma and other cancers. The drug was granted Orphan Drug status in advanced melanoma in December 2005.

<span class="mw-page-title-main">Tumor mutational burden</span>

Tumour mutational burden is a genetic characteristic of tumorous tissue that can be informative to cancer research and treatment. It is defined as the number of non-inherited mutations per million bases (Mb) of investigated genomic sequence, and its measurement has been enabled by next generation sequencing. High TMB and DNA damage repair mutations were discovered to be associated with superior clinical benefit from immune checkpoint blockade therapy by Timothy Chan and colleagues at the Memorial Sloan Kettering Cancer Center.

References

  1. ↑ Bennike, Tue Bjerg; Kastaniegaard, Kenneth; Padurariu, Simona; Gaihede, Michael; Birkelund, Svend; Andersen, Vibeke; Stensballe, Allan (2016). "Proteome stability analysis of snap frozen, RNAlater preserved, and formalin-fixed paraffin-embedded human colon mucosal biopsies". Data in Brief. 6: 942–947. Bibcode:2016DIB.....6..942B. doi:10.1016/j.dib.2016.01.061. PMC   4753390 . PMID   26937473.
  2. ↑ Ribeiro-Silva, Alfredo; Zhang, Haiyu; Jeffrey, Stefanie S. (2007-12-21). "RNA extraction from ten year old formalin-fixed paraffin-embedded breast cancer samples: a comparison of column purification and magnetic bead-based technologies". BMC Molecular Biology. 8: 118. doi: 10.1186/1471-2199-8-118 . ISSN   1471-2199. PMC   2233637 . PMID   18154675.
  3. ↑ Bennike, Tue Bjerg; Kastaniegaard, Kenneth; Padurariu, Simona; Gaihede, Michael; Birkelund, Svend; Andersen, Vibeke; Stensballe, Allan (2016). "⿿Comparing the proteome of snap frozen, RNAlater preserved, and formalin-fixed paraffin-embedded human tissue samples". EuPA Open Proteomics. 10: 9–18. doi:10.1016/j.euprot.2015.10.001. PMC   5988570 . PMID   29900094.
  4. ↑ Code of Federal Regulations, Title 45, Public Welfare Department Of Health And Human Services, Part 46, Protection Of Human Subjects
  5. ↑ Chianese, A.; Santella, B.; Ambrosino, A.; Stelitano, D.; Rinaldi, L.; Galdiero, M.; Zannella, C.; Franci, G. (2021). "Oncolytic Viruses in Combination Therapeutic Approaches with Epigenetic Modulators: Past, Present, and Future Perspectives". Cancers. 13 (11): 2761. doi: 10.3390/cancers13112761 . PMC   8199618 . PMID   34199429.
  6. ↑ Qualman, S. J.; France, M.; Grizzle, W. E.; Livolsi, V. A.; Moskaluk, C. A.; Ramirez, N. C.; Washington, M. K. (2004). "Establishing a tumour bank: banking, informatics and ethics". British Journal of Cancer. 90 (6): 1115–1119. doi:10.1038/sj.bjc.6601678. PMC   2409638 . PMID   15026787.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.